June 2025 – FHIREngine Inc, a healthcare software company dedicated to bringing cancer clinical decision support to improve cancer treatment and extend the reach of oncologists in low-and-middle income countries, today announced a collaboration with the National Comprehensive Cancer Network® (NCCN®), an alliance of leading cancer centers devoted to patient care, research, and education. The joint work between FHIREngine, Inc. and NCCN will enable oncologists to treat more patients with the latest cancer treatment advancements using automated evidence-based pathways and cancer compendia in completing personalized patient journeys.
“Clinical practice guidelines like NCCN’s ensure everyone, including those in areas with limited access and/or resources, has access to the latest recommendations for high-quality cancer care based on the latest evidence and expert consensus,” said Crystal S. Denlinger, MD, Chief Executive Officer, NCCN. “This ongoing collaboration with FHIREngine, Inc will help leverage digital and workflow integration capabilities in pursuit of that goal. We are happy to embark on this work together to help people with cancer achieve better outcomes.”
FHIREngine’s ONCOSure Suite of software tools unifies cancer staging and care pathways, drug therapies, imaging protocols, procedures, biomarkers, treatment recommendations, diagnosis, and SNOMED CT within a single AI/ML-driven platform ensuring highly accurate digitization operated on a secure cloud platform. It enables healthcare professionals to tailor standards to their patients, create and schedule personalized treatment plans. All capabilities of ONCOSure Suite are provided to the user directly via our end-user application or through third party tools such as Patient Management systems and Hospital Management systems or through FHIR services.
Additionally, FHIREngine and NCCN will bring content and capabilities to scale the work of physicians, digitizing and integrating the workflow of the patient journey from staging to treatment to post-monitoring fully incorporating a multi-disciplinary care team of medical oncologists, radiologists and surgeons.
“Our collaboration with NCCN represents a pivotal step in advancing our mission to improve access and outcomes for cancer patients,” said Vikram Simha, co-founder of FHIREngine, Inc. “By integrating our Clinical Decision Support System with NCCN’s gold-standard, evidence- based guidelines and compendia, we’re equipping healthcare systems and physicians to overcome barriers in access and affordability—bringing high-quality cancer care to underserved populations. This collaboration will expand digital access to trusted treatment pathways, enhancing the efficiency and impact of care where it’s needed most.”
For more information, visit NCCN.org and www.oncosure.ai.
About FHIREngine, Inc.
FHIREngine,Inc is a healthcare software company expanding cancer clinical decision support solutions using evidence-based protocols, data and digital capabilities to power smarter care for cancer patients. Through machine learning and AI, clinical evidence, and extending the reach of limited healthcare clinicians, we continue to transform provider and patients’ real-life experiences into improved outcomes using integrated workflows and precision-medicine content.
About The National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives. Visit NCCN.org for more information on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and other initiatives.
Media Contacts
The National Comprehensive Cancer Network:
Rachel Darwin
darwin@nccn.org
FHIREngine, Inc:
Vikram Simha
vsimha@fhirengineinc.com
Disclaimer: This article is sponsored. The editorial team has independently verified the content, but the sponsor's views and opinions may differ from our own.